莫西沙星治疗难治性肺结核咯血的有效性和安全性分析

目的探讨采用莫西沙星治疗难治性肺结核咯血的有效性及安全性。方法选取2011（2010）年3月-2013年6月我院收治的72例难治性肺结核患者作为研究对象，将其随机分为实验组和对照组，对照组采用常规治疗，实验组在常规治疗的基础上予以莫西沙星治疗，比较两组的临床疗效及不良反应发生率。结果分别接受治疗后实验组痊愈14例，显效11例，有效8例，无效3例，总有效率为91．67％；对照组痊愈11例，显效13例，有效4例，无效8例，总有效率为77．78％；对照组不良反应发生率为19．44％．实验组为8．33％，两组总有效率及不良反应发生率比较均有显著性差异，具有统计学意义（P〈0．05）。结论采用莫西沙星治疗难治性肺结核咯血临床疗效显著，安全性高，值得在临床上进一步推广。

Analysis on Efficacy and Safety of Moxifloxacin for Treating Refractory Hemoptysis Caused By Pulmonary Tuberculosis

Objective To explore the efficaoy and safety of moxifloxacin for treating refractory hemoptysis caused by pulmonary tuberculosis. Methods 72 cases of patients with refractory hemoptysis caused by pulmonary tuberculosis admitted in our hospital between March 2011 and June 2013 were adopted as the research object, and randomly divided into the experimental group and the contml group. Conventional treatment was given to the control group, while for the experimental group, in addition to the con- ventional treatment, treatment with moxifloxacin was also implemented. The clinical curative effects and adverse reactions rate of the two groups were compared. Results After the treatment, in the experiment group, 14 cases were cured, 11 cases had marked effect, 8 cases were effective and 3 cases were ineffective, with the total effective rate of 91.67%; while in the control group, 11 cases were cured, 13 cases had marked effect, 4 cases were effective and 8 cases were ineffective, with the total effective rate of 77.78%; In the control group, the incidence of adverse reactions was 19.44%, and that of the experimental group was 8.33%. Both of the total effective rates and the incidences of adverse reactions had significant difference, with statistical significance （P〈0.05）. Conclusion Treating refractory hemoptysis caused by pulmonary tuberculosis with moxifloxacin has the advantages of significant clinical curative effect and high safety, which is worth further promotion in clinic.